Brief: Ultimovacs Announces Publication Of Results From Nipu Phase Ii Trial With Uv1 Vaccination In Mesothelioma In European Journal Of Cancer
02/03/2024 17:43
March 2 (Reuters) - Ultimovacs ASA ULTI.OL :
* REG-ULTIMOVACS ANNOUNCES PUBLICATION OF RESULTS FROM NIPU
PHASE
II TRIAL WITH UV1 VACCINATION IN MESOTHELIOMA IN EUROPEAN
JOURNAL OF CANCER
* ULTIMOVACS - STUDY DID NOT MEET ITS PRIMARY ENDPOINT OF
IMPROVED
PROGRESSION-FREE SURVIVAL (PFS) BASED ON BLINDED INDEPENDENT
CENTRAL REVIEW (BICR)
Source text for Eikon: ID:nGNE29nh7m
Further company coverage: ULTI.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zelluna ASA
See all newsNorway's Zelluna ASA reports Q2 loss
Brief: Zelluna Reports Q2 Total Loss Of NOK 19.7 Million
Brief: Zelluna Says IDMC Recommends Recruitment Of Next Two Patients At First Dose Level
Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
Brief: Zelluna Wins NOK 16 Mln Research Council Of Norway Grant